search
Back to results

Effectiveness and Safety Evaluation of Aqueduct -100 Device

Primary Purpose

Cervix Uteri Dilation

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Aqueduct -100
Sponsored by
Aqueduct Medical Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervix Uteri Dilation focused on measuring cervix, cervical dilation, balloon catheter

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Subjects, females, 18 years of age or older.
  • Subjects undergoing any process that requires dilation (intrauterine procedures)
  • Subjects willing to sign informed consent form.

Exclusion Criteria:

  • Subjects younger than 18 years of age
  • Subject with sex transmitted diseases, or with infectious diseases (HIV, HCV).
  • Subjects unwilling to sign the informed consent form.

Sites / Locations

  • Hospital General Santa Maria del Puerto

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Aqueduct 100 dilation

Arm Description

Uterine cervix dilation through Aqueduct-100 device

Outcomes

Primary Outcome Measures

Percentage of patients with dilation of cervix to the diameter needed to perform the intrauterine procedure using Aqueduct-100 device.
The primary outcome of this study is to determine the efficacy of the Aqueduct-100 device to dilate the uterine cervices to the desired diameter.

Secondary Outcome Measures

Occurrence of Adverse Events
Safety evaluation of using Aqueduct-100

Full Information

First Posted
August 30, 2016
Last Updated
October 20, 2016
Sponsor
Aqueduct Medical Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT02941211
Brief Title
Effectiveness and Safety Evaluation of Aqueduct -100 Device
Official Title
Effectiveness and Safety Evaluation of Aqueduct -100 Device
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
November 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aqueduct Medical Ltd

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Evaluation of efficacy and safety of using Aqueduct -100 - Cervical Dilator Device
Detailed Description
There are predominantly two major dilatation techniques that are employed in dilating the cervix. The first technique uses expansible dry solid material, such as laminaria (seaweed) is inserted into the cervix in its dried stiff form. In the cervix it comes into contact with body fluids that cause the laminaria to swell and enlarge the cervical cavity. The second more widespread procedure, involves the use of series of solid, rod like instruments of graduated diameter used in serial fashion by the physician (Hegar dilators). The physician first inserts a rod like dilator and replaces it with the dilator of next higher diameter. This procedure continues until adequate dilatation occurs. The Problem is that each of the above-mentioned methods has its shortcomings: the use of the laminaria method (rarely done) requires preliminary patient visit, for insertion of the laminaria rod and is extremely slow and typically involves often as much as 10-12 hours for a significant amount of dilatation to occur. The use of rod-like instruments (Hegar) requires general or regional anesthesia, when local anesthetics are used, the patient nevertheless frequently experiences a great amount of discomfort from the procedure. The mechanical dilatation of the cervix demands a large amount of longitudinal force that may damage or even puncture the cervix and the uterus. Aqueduct 100 is a catheter for use in dilating various body cavities and especially the human cervix. The device will enable continuous, fast and safe dilatation of the cervix to a pre-determined diameter as a pre-procedure to intrauterine surgeries.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervix Uteri Dilation
Keywords
cervix, cervical dilation, balloon catheter

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aqueduct 100 dilation
Arm Type
Experimental
Arm Description
Uterine cervix dilation through Aqueduct-100 device
Intervention Type
Device
Intervention Name(s)
Aqueduct -100
Primary Outcome Measure Information:
Title
Percentage of patients with dilation of cervix to the diameter needed to perform the intrauterine procedure using Aqueduct-100 device.
Description
The primary outcome of this study is to determine the efficacy of the Aqueduct-100 device to dilate the uterine cervices to the desired diameter.
Time Frame
Through study completion, approximately 6 months
Secondary Outcome Measure Information:
Title
Occurrence of Adverse Events
Description
Safety evaluation of using Aqueduct-100
Time Frame
Through study completion, approximately 6 months
Other Pre-specified Outcome Measures:
Title
Time frame required to reach desired cervical dilation from start time (insertion of device) to completion of dilation (removal of catheter)
Description
Duration of the dilation procedure.
Time Frame
Through study completion, approximately 6 months
Title
Measurement of physicians' overall satisfaction with the device through the use of a questionnaire
Time Frame
Through study completion, approximately 6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects, females, 18 years of age or older. Subjects undergoing any process that requires dilation (intrauterine procedures) Subjects willing to sign informed consent form. Exclusion Criteria: Subjects younger than 18 years of age Subject with sex transmitted diseases, or with infectious diseases (HIV, HCV). Subjects unwilling to sign the informed consent form.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Javier Vico, MD
Organizational Affiliation
Hospital General Santa Maria del Puerto, Cádiz
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Javier Pantoja, MD
Organizational Affiliation
Hospital General Santa Maria del Puerto, Cádiz
Official's Role
Study Director
Facility Information:
Facility Name
Hospital General Santa Maria del Puerto
City
Cádiz
ZIP/Postal Code
11500
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
An article has been published in the digital edition of "Hysteroscopy Newsletter"
Citations:
PubMed Identifier
16143559
Citation
Mazza E, Nava A, Bauer M, Winter R, Bajka M, Holzapfel GA. Mechanical properties of the human uterine cervix: an in vivo study. Med Image Anal. 2006 Apr;10(2):125-36. doi: 10.1016/j.media.2005.06.001. Epub 2005 Sep 6.
Results Reference
background
Citation
Buhimschi, C.; Buhimschi, I.; Malinow, A.; Saade, G.; Garfield, R.; Weiner, C., The Forces of Labour. Fetal and Maternal Medicine Review 2003, 14 (4), 273-307.
Results Reference
background
PubMed Identifier
17904431
Citation
Myers KM, Paskaleva AP, House M, Socrate S. Mechanical and biochemical properties of human cervical tissue. Acta Biomater. 2008 Jan;4(1):104-16. doi: 10.1016/j.actbio.2007.04.009. Epub 2007 Sep 27.
Results Reference
background
PubMed Identifier
3391017
Citation
Kenyon NJ, Stevens JC, Stewart P, Black MM, Clifford A. A critical investigation of the measurement of the force required to dilate the human uterine cervix. Clin Phys Physiol Meas. 1988 May;9(2):155-61. doi: 10.1088/0143-0815/9/2/008.
Results Reference
background
Citation
S. Febvay, S. Socrate and M.D. House. Biomechanical modeling of cervical tissue. A quantitative investigation of cervical funneling. Proceedings of the ASME 2003 International Mechanical Engineering Congress and Exposition, Washington, D.C., November 2003
Results Reference
background
PubMed Identifier
23088906
Citation
Arsenijevic S, Vukcevic-Globarevic G, Volarevic V, Macuzic I, Todorovic P, Tanaskovic I, Mijailovic M, Raicevic S, Jeremic B. Continuous controllable balloon dilation: a novel approach for cervix dilation. Trials. 2012 Oct 22;13:196. doi: 10.1186/1745-6215-13-196.
Results Reference
background
PubMed Identifier
6849849
Citation
Nicolaides KH, Welch CC, MacPherson MB, Johnson IR, Filshie GM. Lamicel: a new technique for cervical dilatation before first trimester abortion. Br J Obstet Gynaecol. 1983 May;90(5):475-9. doi: 10.1111/j.1471-0528.1983.tb08947.x.
Results Reference
background
Links:
URL
https://www.youtube.com/watch?v=nJY3Y-hpdyw
Description
Aqueduct-100 functioning

Learn more about this trial

Effectiveness and Safety Evaluation of Aqueduct -100 Device

We'll reach out to this number within 24 hrs